Cutaneous T-cell lymphoma (CTCL) - brentuximab vedotin - initial authority application form (PB268)

Use this form to apply for initial PBS-subsidised treatment with brentuximab vedotin for cutaneous T-cell lymphoma.

Page last updated: 17 June 2024.
QC 49701